WDC at Dementia Forum X: A global action on dementia

WDC Chair, Yves Joanette and WDC Member and Trustee, George Vradenburg were both active participants in this year’s highly successful Dementia Forum X, in Stockholm, Sweden on 18th May 2017. Yves Joanette took part in a group discussion and Q&A session called Big Picture Dialogue and George Vradenburg was one of the speakers in a moderator led series of Inspirational Conversations.

George Vradenburg

George Vradenburg convenes the Global CEO Initiative on Alzheimer’s (CEOi), a patient-centered industry coalition working with government, researchers and patients to develop and deliver innovative medicines to those touched by dementia and improve their quality of care. He also chairs the Global Alzheimer's Platform Foundation (GAP) and is chair and co-founder of USAgainstAlzheimer’s (USA2), which convenes CEOi and is a “disruptive,” entrepreneurial and patient-focused US based NGO committed to stopping Alzheimer’s disease by 2020.

Dr Husseini Manji

Husseini K Manji, MD, FRCPC is Global Head, J&J Science for Minds, and immediate past Therapeutic Head for Neuroscience at Janssen Research & Development, one of the Johnson & Johnson pharmaceutical companies. His research has investigated disease- and treatment-induced changes in gene and protein networks that regulate synaptic and neural plasticity in neuropsychiatric disorders. This has led to the FDA approval of the first novel antidepressant mechanism (NMDA-antagonism) in decades and has been actively involved in developing biomarkers to help refine these diseases.

WDC chair gives lecture to the Italian Society for Dementia

World Dementia Council (WDC) Chair, Professor Yves Joanette, gave an invited lecture at the twelfth annual meeting of the Italian Society for Dementia in Florence, Italy on Thursday 16th March 2017. In his lecture, “A Global Response to the Global Challenge of Dementia,” Professor Joanette talked about the many diseases that cause dementia; the increase in the global impact of dementia, including in terms of the number of people affected and the spiralling cost of the disease; and the fear that dementia causes in older people.